Table 1 Parameter notations, definitions, and sources.
From: Age-Structured Population Modeling of HPV-related Cervical Cancer in Texas and US
Parameter | Definition | Reference |
|---|---|---|
Δ | Rate of hysterectomy | |
π 2 | Rate of progression from CIN 2 to CIN 3 | |
π 3 | Rate of progression from CIN 3 to CIS | |
π 5 | Rate of progression from CIS to local cervical cancer | |
γ fb | Proportion of regression CIN without infection | |
d | Transfer rate from age group i | |
μ | Death rate | |
pc l | Relative partner acquisition rate for sexual activity group | |
pa i | Relative partner acquisition rate for age group | |
\({\bar{c}}_{j}\) | Mean partner acquisition rate | |
σ z | Rate of waning immunity following recovery | |
γ | Rate of recovery from HPV infection | |
θ sz | Reactivation rate following seroconversion | |
θ szs | Reactivation rate, did not seroconvert | |
ι | Probability of seroconversion following HPV clearance | |
ψ z | Degree of protection following seroconversion | |
ψ zs | Degree of protection following no seroconversion | |
\({\sigma }_{v}^{I}\) | Rate of waning immunity following vaccination | |
\({\sigma }_{v}^{II}\) | Rate of waning immunity following vaccination | |
σ q | Rate of waning immunity following recovery | |
σ qs | Rate of waning immunity following recovery | |
ψ q | Degree of protection following recovery of an infection in previously vaccinated individuals with seroconversion | Estimated |
ψ qs | Degree of protection following recovery of an infection in previously vaccinated individuals with seroconversion | Estimated |
θ sq | Reactivation rate in patients who are recovered, vaccinated, and seroconverted | Estimated |
θ sqs | Reactivation rate in patients who are recovered, vaccinated, and no seroconversion | |
χ | Rate of local cervical cancer–associated death | |
prf | Proportion of infections that are destined to be persistent | |
τ 32 | Rate of regression from CIN 3 to CIN 2 | |
π L | Rate of progression from local to regional cervical cancer | |
π R | Rate of progression from local to regional cervical cancer | |
\({\psi }_{p}^{I}\) | Degree of protection following seroconversion, vaccinated | Estimated |
\({\psi }_{p}^{II}\) | Degree of protection following seroconversion, vaccinated | Estimated |
Φ 1 | Proportion receiving only 1 dose | Estimated |
Φ 2 | Proportion receiving only 2 doses | Estimated |
ψ v1 | Degree of protection with 1 dose | |
ψ v2 | Degree of protection with 2 doses | |
α | Relative rate of recovery from breakthrough infection | |
θ | %Rate of progression from HPV infection to CIN 2,3 | |
θ t | %Rate of progression from HPV infection to CIN 2,3 | |
τ | Rate of regression from CIN 2,3 to normal or HPV | |
θ r | Recurrence rate of treated CIN 2,3 | |
\({\theta }_{p}^{I}\) | Rate of progression from breakthrough infection to CIN 2,3 | Estimated |
\({\theta }_{p}^{II}\) | Rate of progression from breakthrough infection to CIN 2,3 | Estimated |
Ω | Cure rate of local cervical cancer | |
\({\theta }_{tw}^{I}\) | Rate of progression to CIN2/3 in patients that are vaccinated with 1 dose, then are infected | Estimated |
\({\theta }_{tw}^{II}\) | Rate of progression to CIN2/3 in patients that are vaccinated with 2 doses, then are infected | Estimated |
θ tws | Rate of progression to CIN2/3 in patients that are infected, vaccinated, and have waning immunity | Estimated |
θ ps | Rate of progression to CIN2/3 in patients that are persistently infected and vaccinated | Estimated |
prev | Proportion of cured CIN 2,3/CIS still infected | |
Γ | Cure rate of CIN 2,3, CIS | |
ϕ m | Proportion of newborn vaccinated, male persons | Estimated |
ϕ f | Proportion of newborn vaccinated, female persons | Estimated |
B | Newborn | |
ϕ cm | Vaccine uptake rate with first dose, male persons | |
ϕ cf | Vaccine uptake rate with first dose, female persons | |
κ | Detection rate of CIN 2,3, CIS | |
ν | Detection rate of local cancer |
